Insider · CIK 0001647102
Adele M. Gulfo
director
Files at NPO (Enpro Inc.), TYRA (Tyra Biosciences, Inc.), NAMS (NewAmsterdam Pharma Co N.V.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +5 | $287.16 | $1,436 | 5,282 | 25 d ago |
| Sep 16, 2026 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +1 | $287.16 | $165 | 5,282 | 25 d ago |
| Jun 18, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +7 | $185.86 | $1,301 | 4,896 | Jun 20, 2025 |
| Jun 18, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +0 | $185.86 | $48 | 4,896 | Jun 20, 2025 |
| Apr 15, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Ordinary Shares | +10,860 | - | - | 10,860 | Apr 17, 2025 |
| Apr 15, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Option (right to buy)derivative | +50,700 | $0.00 | $0 | 50,700 | Apr 17, 2025 |
| Mar 31, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +155 | $161.79 | $25k | 4,889 | Apr 1, 2025 |
| Mar 19, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +7 | $175.76 | $1,230 | 4,734 | Mar 20, 2025 |
| Feb 13, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +685 | $182.27 | $125k | 4,727 | Feb 13, 2025 |
| Jan 29, 2025 | TYRA Tyra Biosciences, Inc. | AGrant or award Common Stock (Right to Buy)derivative | +37,200 | $0.00 | $0 | 37,200 | Jan 31, 2025 |
| Dec 18, 2024 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +7 | $175.86 | $1,231 | 4,042 | Dec 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.